Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Sida 1 från 637 resultat
Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD OF THE INVENTION
This invention relates to pharmaceutical compositions useful for treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration, and to methods for using the compositions.
BACKGROUND OF THE INVENTION
Neurotrophic factors exhibit a trophic effect
Hypoxia-responsive nanoparticle for therapy and imaging of hypoxia-involving diseases
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
The present invention relates to nanoparticles that change their properties under hypoxic conditions, and thus can be used for the diagnosis and treatment of hypoxia-related diseases.
BACKGROUND ART
Hypoxia, a pathological condition deprived of adequate oxygen supply, is a hallmark
Identification of compounds that modify transcriptional responses to hypoxia
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
This invention relates to methods for identifying compounds that modify transcriptional responses to hypoxia.
As solid tumors evolve from a single malignant cell into a multicellular mass, oxygen tension in the tumor microenvironment drops as the passive diffusional
FROG/TOAD conditionally silenced vectors for hypoxia gene therapy
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
Embodiments of the invention comprise methods of treating hypoxia and associated conditions. In particular, directional therapeutic angiogenesis induced in patients via a conditionally silenced vector expressing a desired factor.
BACKGROUND
Therapeutic angiogenesis is a
cDNAs and proteins involved in hypoxia, circadian and orphan signal transduction pathways, and methods of use
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
This invention relates to the field of molecular signaling and physiological responses to external stimuli. In particular, this invention provides nucleic acid molecules and proteins that constitute new members of the bHLH-PAS superfamily of transcription
cDNAs and proteins involved in hypoxia, circadian and orphan signal transduction pathways, and methods of use
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
This invention relates to the field of molecular signaling and physiological responses to external stimuli. In particular, this invention provides nucleic acid molecules and proteins that constitute new members of the bHLH-PAS superfamily of transcription
Nitroimidazole-amino acid hypoxia contrast medium, preparation method and use thereof
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to a medical nuclear contrast medium, and more particularly to a nitroimidazole-amino acid hypoxia contrast medium, a precursor, preparation method, and use thereof.
2. Description of the Related Art
Tumors have become one
Sequences characteristic of hypoxia-regulated gene transcription
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
1. Technical Field
The present invention relates to the identification of genes that are differentially expressed in hypoxia and use of the genes and gene products for diagnosis and therapeutic intervention. The invention further relates to identification of
Sequences characteristic of hypoxia-regulated gene transcription
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
1. Technical Field
The present invention relates to the identification of genes that are differentially expressed in hypoxia and use of the genes and gene products for diagnosis and therapeutic intervention. The invention further relates to identification of
Compositions and methods for treating neural anoxia and spreading depression
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
The present invention relates to compositions and methods for protecting neural tissue from anoxia and/or spreading depression. The present invention further relates to compositions and methods for mitigating side effects associated with pharmaceuticals that manipulate the
Compounds for enhancing hypoxia inducible factor activity and methods of use
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Hypoxia inducible factor-1 (HIF-1) is a heterodimeric transcriptional activator that regulates the expression of genes involved in adaptation to hypoxic stress. HIF-1 is composed of two subunits referred to as HIF-1.alpha. and HIF-1.beta.. These subunits are expressly
Rhenium and technetium complexes containing a hypoxia-localizing moiety
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Many of the procedures presently conducted in the field of nuclear medicine involve radiopharmaceuticals which provide diagnostic images of bloo flow (perfusion) in the major organs and in tumors. The regional uptake of these radiopharmaceuticals within the organ of
Rhenium and technetium complexes containing a hypoxia-localizing moiety
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF INVENTION
Many of the procedures presently conducted in the field of nuclear medicine involve radiopharmaceuticals which provide diagnostic images of blood flow (perfusion) in the major organs and in tumors. The regional uptake of these radiopharmaceuticals within the organ of interest
Rhenium and technetium complexes containing a hypoxia-localizing moiety
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Many of the procedures presently conducted in the field of nuclear medicine involve radiopharmaceuticals which provide diagnostic images of blood flow (perfusion) in the major organs and in tumors. The regional uptake of these radiopharmaceuticals within the organ of
Rhenium and technetium complexes containing a hypoxia-localizing moiety
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Many of the procedures presently conducted in the field of nuclear medicine involve radiopharmaceuticals which provide diagnostic images of blood flow (perfusion) in the major organs and in tumors. The regional uptake of these radiopharmaceuticals within the organ of
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
